News Sentiment

BBIO sentiment intelligence

BridgeBio Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 85.89 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+11.3% over one week, +28.6% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

BBIO6017175 Bond Risk Profile

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 11.3% Price confirming higher
Trend fit Trend inactive 28.6% over four weeks
Fair value 102.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 29
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 9
TradingView 7
Investing.com 6
simplywall.st 5
Moomoo 2
Seeking Alpha 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Analyst action 3
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
TradingView Direct company coverage

BBIO6017175 Bond Risk Profile

This page provides a risk profile for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond, identified by FINRA BBIO6017175. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliabilit

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 05:43
Source
TradingView
Moomoo Direct company coverage

BridgeBio Pharma(BBIO.US) Director Sells US$13.16 Million in Common Stock

A director at BridgeBio Pharma (BBIO.US) recently sold common stock valued at approximately US$13.16 million. This transaction involved the sale of 468,546 shares at an average price of US$28.09 per share. Following this sale, the director still retains 5,798,064 shares of the co

Tone
Negative 28/100
Event
Market update
Published
14 Jul 2026 02:43
Source
Moomoo
TradingView Direct company coverage

BBIO6336503 Bond Profile — Key Metrics

This article provides key metrics for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (BBIO6336503). It outlines details such as the issuer, issue date, maturity date, outstanding amount, face value, and coupon rate. The bond's profile highlights that BridgeBio Pharma, Inc. foc

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 00:43
Source
TradingView
Investing.com Direct company coverage

BridgeBio Pharma director Jennifer E. Cook sells $13.16m in shares

Jennifer E. Cook, a director at BridgeBio Pharma, sold shares totaling $13.16 million after exercising stock options, leading to a net direct holding of 8,383 shares. These transactions were part of a Rule 10b5-1 sales plan. The company's stock is trading near its 52-week high an

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:40
Source
Investing.com
Stock Titan Direct company coverage

BridgeBio Pharma (BBIO) director sells 17167.0000 shares after option exercise

BridgeBio Pharma director Andrea Ellis reported an exercise-and-sale sequence on July 9, 2026, involving 17,167 shares of common stock. She exercised stock options at $16.75 per share and subsequently sold all 17,167 shares at $84.00 per share under a Rule 10b5-1 sales plan estab

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:40
Source
Stock Titan
Investing.com Direct company coverage

BridgeBio Pharma director Andrea Ellis sells $1.44m in stock

BridgeBio Pharma director Andrea Ellis sold $1.44 million worth of company common stock on July 9, 2026, as part of a Rule 10b5-1 sales plan adopted in December 2025. This transaction followed her exercise of stock options for 17,167 shares at $16.75 per share. The stock is curre

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:40
Source
Investing.com
Stock Titan Direct company coverage

BridgeBio Pharma (NASDAQ: BBIO) director exercises options, sells 148,589 shares

BridgeBio Pharma director Jennifer E. Cook exercised stock options for 148,589 shares and then sold an equal number of shares in open-market transactions on July 9, 2026. The sales, totaling approximately $13.16 million, were conducted pursuant to a pre-arranged Rule 10b5-1 sales

Tone
Negative 41/100
Event
Market update
Published
13 Jul 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

US10806XAH5 Bond Profile — Key Metrics

This article provides key metrics for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (US10806XAH5), traded on the Frankfurt Stock Exchange. It details the bond's coupon rate, issue date, maturity date, and face value, along with a brief description of BridgeBio Pharma, Inc. Th

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 19:40
Source
TradingView
Simply Wall Street Direct company coverage

BridgeBio Pharma (BBIO) Following Wainua Trial Setback Still Looks Undervalued

BridgeBio Pharma (BBIO) stock experienced volatility after AstraZeneca's Wainua trial setback, impacting expectations for Attruby. Despite this, the company's valuation against an average analyst target and intrinsic value estimates suggests it may still be undervalued, driven by

Tone
Positive 65/100
Event
Analyst action
Published
12 Jul 2026 12:10
Source
Simply Wall Street
The Manila Times Direct company coverage

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. announced equity grants to 37 new employees, totaling 83,283 restricted stock units of the Company’s common stock. These grants were approved by the compensation committee on July 7, 2026, and are considered inducement material for employment, compliant wit

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 19:39
Source
The Manila Times
Stock Titan Direct company coverage

Viking Global’s BridgeBio Pharma (NASDAQ: BBIO) stake moves just under 5%

Viking Global Investors and its affiliated entities have reported that their beneficial ownership in BridgeBio Pharma (NASDAQ: BBIO) has fallen just under 5%, specifically to 4.9951% as of July 9, 2026. This change was disclosed in an Amendment No. 12 to their Schedule 13D filing

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 Jul 2026 13:09
Source
Stock Titan
Quartr Direct company coverage

BridgeBio (BBIO) Q1 2025 earnings summary

BridgeBio's Q1 2025 results show strong initial sales for Attruby and significant total revenue. The company reported a widened net loss due to increased SG&A and interest expenses but maintains a robust pipeline with several phase three readouts expected within the next year. Wi

Tone
Positive 74/100
Event
Earnings
Published
11 Jul 2026 00:40
Source
Quartr
Stock Titan Direct company coverage

BridgeBio hands new hires 83,283 stock-unit incentive awards

BridgeBio Pharma (Nasdaq: BBIO) reported that its board compensation committee approved inducement equity grants of restricted stock units (RSUs) to 37 new employees, totaling 83,283 common shares, on July 7, 2026. These RSUs will vest one-fourth on August 16, 2027, with the rema

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:39
Source
Stock Titan
TradingView Direct company coverage

How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High

BridgeBio Pharma's (BBIO) stock surged to a 52-week high after AstraZeneca's (AZN) late-stage clinical trial for its ATTR-CM drug, Wainua, failed to meet its primary endpoint. This setback is seen as beneficial for BridgeBio's Attruby, its sole marketed drug for ATTR-CM, strength

Tone
Positive 73/100
Event
Market update
Published
10 Jul 2026 16:39
Source
TradingView
Trefis Direct company coverage

Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?

BridgeBio Pharma (BBIO) is experiencing a powerful transition, with its lead drug Attruby driving significant revenue growth and three more drugs in the pipeline. Despite a high market valuation and lack of profitability, the company is well-capitalized to pursue its ambitious la

Tone
Positive 65/100
Event
Earnings
Published
10 Jul 2026 12:39
Source
Trefis
Quartr Direct company coverage

BridgeBio (BBIO) Q3 2025 earnings summary

BridgeBio (BBIO) reported strong Q3 2025 earnings, with total revenue reaching $120.7 million, primarily driven by the successful commercial launches of Attruby and Beyonttra. The company maintained a robust financial position with $645.9 million in cash and plans for NDA filings

Tone
Positive 75/100
Event
Earnings
Published
10 Jul 2026 02:39
Source
Quartr
www.timothysykes.com Direct company coverage

BridgeBio Pharma BBIO Jumps As Infigratinib Data, $1B Raise Fire Up Bulls

BridgeBio Pharma (BBIO) shares surged over 15% following positive Phase 3 trial results for its drug infigratinib in pediatric achondroplasia, which also secured publication in the New England Journal of Medicine. The company plans FDA and EMA filings in 2026 for a potential U.S.

Tone
Positive 94/100
Event
Earnings
Published
09 Jul 2026 20:43
Source
www.timothysykes.com
Stock Titan Direct company coverage

[144] BridgeBio Pharma, Inc. SEC Filing

This article announces a Form 144 SEC filing by BridgeBio Pharma, Inc. (BBIO). The filing details a proposed sale of 17,167 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,442,028. The shares were acquired on J

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:43
Source
Stock Titan
StocksToTrade Direct company coverage

BridgeBio Pharma BBIO Jumps On Trial Win And $1B Raise

BridgeBio Pharma (BBIO) shares jumped over 13% following positive Phase 3 clinical trial results for its oral infigratinib in pediatric achondroplasia, which showed statistically significant improvements in body proportionality and arm span. The company also secured up to $1 bill

Tone
Positive 73/100
Event
Earnings
Published
09 Jul 2026 16:43
Source
StocksToTrade
Investing.com Direct company coverage

BridgeBio Pharma stock reaches all-time high at 86.0 USD

BridgeBio Pharma Inc. (BBIO) stock hit an all-time high of $86.00, pushing its market capitalization to $15.4 billion, reflecting a significant 69.29% increase over the past year. This milestone comes after recent developments including a $1 billion preferred equity investment an

Tone
Positive 76/100
Event
Market update
Published
09 Jul 2026 14:43
Source
Investing.com
Moomoo Direct company coverage

BridgeBio Pharma Up Over 14%, on Track for Record High Close -- Data Talk

BridgeBio Pharma's stock is up over 14% and is on track for a record high close. This significant jump suggests positive market reaction, likely driven by recent company developments or news.

Tone
Positive 91/100
Event
Market update
Published
09 Jul 2026 13:43
Source
Moomoo
Simply Wall Street Direct company coverage

BridgeBio Pharma (BBIO) Is Up 5.1% After Kidney Data Boost Attruby And Infigratinib Advances

BridgeBio Pharma reported positive Phase 3 data for infigratinib and new post-hoc analyses suggesting kidney-protective effects of acoramidis (Attruby), alongside securing up to $1 billion in preferred equity financing. These developments aim to expand Attruby’s profile and advan

Tone
Positive 82/100
Event
Market update
Published
09 Jul 2026 13:43
Source
Simply Wall Street
GuruFocus Direct company coverage

BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback

Shares of BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) surged by approximately 15% and 18%, respectively, after AstraZeneca's (AZN) and Ionis Pharma's (IONS) late-stage trial for a competing transthyretin amyloid cardiomyopathy (ATTR-CM) treatment failed. This setback for ri

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 12:27
Source
GuruFocus